Neuren Pharmaceuticals Limited (NURPF) Price & Analysis

55 Followers

NURPF Stock Chart & Stats

$8.82

$0.19(2.50%)

At close: Jan 02 4:00 PM EST

$8.82

$0.19(2.50%)

Day’s Range― - ―

52-Week Range$7.70 - $14.80

Previous CloseN/A

Volume300.00

Average Volume (3M)183.00

Market Cap

$1.47B

Enterprise Value$1.70B

Total Cash (Recent Filing)$296.12M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)70.8

Beta0.41

Next Earnings

Aug 25, 2026

EPS Estimate

0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.24

Shares Outstanding126,773,980

10 Day Avg. Volume0

30 Day Avg. Volume183

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)7.05

Price to Sales (P/S)36.92

P/FCF Ratio19.03

Enterprise Value/Market Cap1.16

Enterprise Value/Revenue26.30

Enterprise Value/Gross Profit34.19

Enterprise Value/Ebitda77.10

Forecast

1Y Price Target

$15.30

Price Target Upside73.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)0.12

Revenue Forecast (FY)$66.11M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetNo reported debt across recent years materially lowers financial risk and preserves optionality. For a small biopharma, zero leverage provides durable flexibility to fund development via partners or cash, reduces refinancing/default risk and supports long-term R&D planning.

Sustained Profitability & High MarginsThree consecutive profitable years with very high gross margins indicate structural cost advantages and earnings power uncommon among early biotechs. This margin profile supports reinvestment in pipeline programs and improves resilience to revenue swings over a multi‑month horizon.

Partnering / Royalty Business ModelAn out‑licensing model shifts commercialization risk to partners while securing royalties and milestone upside. This durable model reduces fixed commercialization costs, lets Neuren focus on R&D, and can produce recurring, low-capex revenue streams if partner execution continues.

Bears Say

Revenue VolatilityLarge swings in top-line undermine forecasting and make recurring revenue visibility weak. For a licensor dependent on royalties and milestones, volatile sales or milestone timing can produce lumpy income, complicating multi‑period budgeting and investment decisions.

Inconsistent Cash ConversionIntermittent conversion of profits into cash indicates timing and working‑capital sensitivity. Periods of negative cash flow despite accounting profits reduce the company’s ability to self-fund programs reliably and increase dependency on partner milestones or external financing during down cycles.

Small Team & Partner DependenceA lean organization (nine employees) plus reliance on partners limits internal commercialization capacity and increases exposure to third‑party execution and timing. This structural dependence constrains direct control over revenue realization and amplifies milestone/royalty concentration risk.

Neuren Pharmaceuticals Limited News

Neuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has provided an announcement. Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has secured a...

7d ago

Neuren Pharmaceuticals Seeks ASX Quotation for 450,000 New Shares

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has shared an announcement. Neuren Pharmaceuticals has applied to the ASX for...

18d ago

Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) just unveiled an update. Neuren Pharmaceuticals has notified the market of the...

1M ago

Neuren Investors Back Board and CEO Options but Reject Constitution Changes

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an announcement. Shareholders of Neuren Pharmaceuticals have backed the re-election...

1M ago

Neuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an update. Neuren reported strong financial performance for 2025, underpinned...

1M ago

Neuren Advances NNZ-2591 Into Phase 3 Extension, Deepening Its Rare-Disease Pipeline

Neuren Pharmaceuticals Limited ($NURPF) announced an update on their ongoing clinical study. Neuren Pharmaceuticals Ltd. (NURPF) has launched...

1M ago

NURPF

Neuren launches Investor Hub to bolster engagement as neurological pipeline advances

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an update. Neuren Pharmaceuticals has launched an Investor Hub and...

2M ago

Neuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an announcement. Neuren Pharmaceuticals has reported an update on its...

2M ago

Neuren Rides 20% DAYBUE Sales Growth and Strong STIX Launch in Q1 2026

The latest announcement is out from Neuren Pharmaceuticals Limited ( ($AU:NEU) ). Neuren Pharmaceuticals reported strong momentum in...

2M ago

Neuren Updates Market on Ongoing On-Market Share Buy-Back

The latest update is out from Neuren Pharmaceuticals Limited ( ($AU:NEU) ). Neuren Pharmaceuticals Limited has provided an...

2M ago

NURPF FAQ

What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?

Neuren Pharmaceuticals Limited lowest stock price was $7.70 and its highest was $14.80 in the past 12 months.

What is Neuren Pharmaceuticals Limited’s market cap?

Neuren Pharmaceuticals Limited’s market cap is $1.47B.

When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?

Neuren Pharmaceuticals Limited’s upcoming earnings report date is Aug 25, 2026 which is in 50 days.

How were Neuren Pharmaceuticals Limited’s earnings last quarter?

Neuren Pharmaceuticals Limited released its earnings results on Feb 26, 2026. The company reported $0.082 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.072.

Is Neuren Pharmaceuticals Limited overvalued?

According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neuren Pharmaceuticals Limited pay dividends?

Neuren Pharmaceuticals Limited does not currently pay dividends.

What is Neuren Pharmaceuticals Limited’s EPS estimate?

Neuren Pharmaceuticals Limited’s EPS estimate is 0.03.

How many shares outstanding does Neuren Pharmaceuticals Limited have?

Neuren Pharmaceuticals Limited has 126,773,980 shares outstanding.

What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?

Neuren Pharmaceuticals Limited reported an EPS of $0.082 in its last earnings report, beating expectations of $0.01. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in NURPF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neuren Pharmaceuticals Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

9.20%

Trailing 12-Months

Asset Growth

-9.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Neuren Pharmaceuticals Limited (NURPF) Earnings & Revenues

Historic Earnings Reports

NURPF Stock 12 Month Forecast

Average Price Target

$15.30

▲(73.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","12":"$12","17":"$17","9.5":"$9.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.53828,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.297908999999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.1617145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9.5,12,14.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.46,13.69679076923077,13.933581538461539,14.170372307692308,14.407163076923078,14.643953846153847,14.880744615384616,15.117535384615385,15.354326153846154,15.591116923076925,15.827907692307694,16.064698461538462,16.30148923076923,{"y":16.53828,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.46,13.601377615384616,13.742755230769232,13.884132846153847,14.025510461538461,14.166888076923078,14.308265692307693,14.449643307692307,14.591020923076922,14.732398538461538,14.873776153846153,15.015153769230768,15.156531384615384,{"y":15.297908999999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.46,13.437054961538463,13.414109923076923,13.391164884615385,13.368219846153847,13.345274807692308,13.32232976923077,13.299384730769232,13.276439692307694,13.253494653846154,13.230549615384616,13.207604576923078,13.184659538461538,{"y":13.1617145,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.805,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.735,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.325,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.906,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.525,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.825,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.875,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >